Novo Nordisk halts work on cell therapy for diabetes to cut costs, Bloomberg News reports

Core Insights - Novo Nordisk has decided to cut its cell therapy division, which was focused on finding a cure for type 1 diabetes [1] Company Actions - The decision to cut the cell therapy division indicates a strategic shift for Novo Nordisk, as it moves away from this specific area of research [1]